• An early-stage Biogen, specializing in brain and nerve disorder drugs.
• It's like a biotech startup, similar to an early Moderna, but focused on developing innovative treatments for central nervous system diseases.

• CY6463: A CNS-penetrant sGC stimulator currently in clinical trials for neurological conditions such as mitochondrial encephalomyopathy (MELAS), Alzheimer's disease with vascular pathology, and schizophrenia.
• Praliciguat: An orally administered systemic sGC stimulator undergoing Phase II studies for resistant hypertension and diabetic nephropathy.
• Olinciguat: An orally administered vascular sGC stimulator in Phase II studies for the treatment of sickle cell disease.
• CY3018: A drug candidate in development aimed at treating disorders of the central nervous system.

Cyclerion Therapeutics (CYCN) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of medicines. As such, it does not currently sell approved pharmaceutical products directly to individuals or healthcare providers. Its primary revenue streams and "customers" at this stage typically come from collaborations, partnerships, and licensing agreements with other pharmaceutical companies.

Based on the provided information, Cyclerion Therapeutics has the following major customer:

• Akebia Therapeutics, Inc. (Symbol: AKBA)

This is due to a license agreement for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including a pharmaceutical compound and other related products and forms.

Akebia Therapeutics, Inc. (AKBA)

Regina M. Graul, Ph.D. President and Chief Executive Officer

Regina Graul has served as President of Cyclerion Therapeutics since December 2023 and was promoted to Chief Executive Officer in August 2024. Before her appointment as President, Dr. Graul was Vice President, Program Executive at EQRx Therapeutics, Inc. from February 2021. She also previously worked at Cyclerion as Senior Director, Global Development Leader from April 2019 to February 2021. Dr. Graul began her career in the biopharmaceutical industry at Ironwood Pharmaceuticals (formerly Microbia Inc.) as a medicinal chemist.

Rhonda M. Chicko, C.P.A. Chief Financial Officer

Rhonda Chicko has served as Chief Financial Officer for Cyclerion Therapeutics since January 2024, acting as a consultant to the company. Since October 2019, Ms. Chicko has provided consulting services as a chief financial officer to various life science companies. Her prior roles include Chief Financial Officer of Scholar Rock from April 2018 to October 2019, and Vice President of Finance at Editas Medicine from September 2015 to March 2018. Before that, Ms. Chicko spent ten years at Ironwood Pharmaceuticals, Inc. (2005-2015) in financial positions, culminating as Senior Director, Finance and Tax.

Here are the key risks to Cyclerion Therapeutics (CYCN):

1. Clinical Development and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, Cyclerion's business success is heavily dependent on the successful completion of clinical trials and the subsequent regulatory approval of its product candidates. The failure of any of its drug candidates, such as CY6463, Praliciguat, Olinciguat, or CY3018, to demonstrate efficacy and safety in trials, or to gain regulatory approval, would significantly jeopardize the company's future prospects and ability to generate revenue.
2. Financial Instability and Need for Additional Capital: Cyclerion Therapeutics faces significant financial challenges, characterized by low and non-recurring revenue, widening losses, and a high operational burn rate. While the company has a clean balance sheet with no debt, it has reported a deepening cash crunch and limited cash reserves, necessitating the need to raise additional capital to fund its ongoing research and development activities. The market has reportedly priced in "significant dilution risk or a high probability of pipeline failure," and there is substantial doubt regarding the company's ability to continue as a going concern.
3. Reliance on Third Parties and Intellectual Property Risk: Cyclerion relies on third parties for critical aspects of its operations, including conducting clinical studies and manufacturing drug supplies. Any disruptions or failures in these third-party relationships could adversely impact the company's development timelines and operational efficiency. Additionally, the company's ability to adequately protect its intellectual property is crucial for its long-term viability and competitive position.

Cyclerion Therapeutics (CYCN) operates in several therapeutic areas with significant addressable markets for its pipeline products.

CY6463

• Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS): The market for MELAS syndrome across the 7 major markets (7MM: United States, EU4 (Germany, France, Italy, Spain), United Kingdom, and Japan) was valued at approximately USD 170.5 million in 2024. This market is projected to reach between USD 494.2 million and USD 512.2 million by 2035, growing at a CAGR of 10.16% to 10.55% from 2025 to 2035.
• Alzheimer's Disease with Vascular Pathology:
  • The broader Alzheimer's disease market in the 7MM (United States, EU4, United Kingdom, and Japan) was valued at approximately USD 5,048 million in 2025. This market is projected to reach USD 34,335 million by 2034, with a CAGR of 23.7%.
  • Another report estimates the Alzheimer's disease market across eight major markets (8MM: China, France, Germany, Japan, Italy, Spain, the UK, and the US) to grow from $2.4 billion in 2023 to $17 billion by 2033, at a CAGR of 21.8%.
  • For vascular dementia, a related condition, the market across the 7MM (United States, EU4, United Kingdom, and Japan) was valued at USD 2.3 billion in 2024 and is expected to reach between USD 3.5 billion and USD 3.6 billion by 2035, with a CAGR of 3.96% to 4.18%. The global vascular dementia market is estimated to be valued at USD 3.23 billion in 2025 and is expected to reach USD 4.34 billion by 2032, growing at a CAGR of 4.3% from 2025 to 2032.
• Schizophrenia: The global schizophrenia therapeutics market was estimated at USD 8.18 billion in 2024 and is projected to reach USD 11.19 billion by 2030, with a CAGR of 5.6% from 2025 to 2030. Other estimates for the global schizophrenia treatment market in 2024 ranged from USD 7.97 billion to USD 7.5 billion. North America was the largest revenue-generating market in 2024.

Praliciguat

• Resistant Hypertension: The treatment-resistant hypertension market size in the 7MM (United States, EU4, United Kingdom, and Japan) was valued at approximately USD 6,958 million in 2025. This market is projected to grow at a CAGR of 6.30% by 2034. The United States accounted for the highest market size within the 7MM in 2024, approximately USD 6,210 million.
• Diabetic Nephropathy: The global diabetic nephropathy market size was valued at USD 3.74 billion in 2024 and is projected to reach USD 6.09 billion by 2032, with a CAGR of 6.30% during the forecast period of 2025 to 2032. Other reports estimate the global market size at USD 3.4 billion in 2025, projected to reach USD 4.6 billion by 2030, with a CAGR of 6.2%.

Olinciguat

• Sickle Cell Disease: The global sickle cell disease treatment market size was estimated at USD 3.94 billion in 2025 and is projected to reach USD 20.47 billion by 2034, growing at a CAGR of 20.10% from 2026 to 2034. Another estimate for the global market in 2025 is USD 3.20 billion, expanding to USD 8.81 billion by 2032, with a CAGR of 15.6%. The United States dominated the sickle cell disease treatment market with a market share of 63.35% in 2025.

CY3018

• Disorders of the Central Nervous System (CNS): The global central nervous system therapeutics market size was valued at approximately USD 178.9 billion in 2024. Other estimates for the global CNS therapeutics market in 2024 range from USD 137.04 billion to USD 148.7 billion. This market is projected to reach between USD 243.6 billion and USD 273.32 billion by 2033, with CAGRs ranging from 5.64% to 9.1% during the forecast periods. North America is consistently identified as the leading market in CNS therapeutics.

Cyclerion Therapeutics (CYCN) has strategically shifted its focus from its legacy soluble guanylate cyclase (sGC) stimulator portfolio to a new pipeline centered on neuropsychiatric diseases. Over the next 2-3 years, the company's expected drivers of future revenue growth will primarily stem from the monetization of its divested sGC assets and the advancement of its new lead candidate, CYC-126.

Here are the key drivers:

1. Milestone Payments and Royalties from Praliciguat: Cyclerion has renegotiated its license agreement for praliciguat with Akebia Therapeutics. This agreement includes upfront and near-term payments, as well as the potential for future development, regulatory, and commercialization milestone payments totaling up to $560 million. Additionally, Cyclerion is eligible to receive tiered sales royalties ranging from mid-single-digits to 20% on future sales of praliciguat.
2. Payments from Olinciguat License Option Agreement: The company has entered into an exclusive license option agreement for olinciguat with an entity controlled by CVCO Therapeutics. This agreement provides for the reimbursement of certain intellectual property expenses during the option period and could lead to additional revenue streams if the option is exercised and the program advances.
3. Value from Equity Stake in Tisento Therapeutics: Cyclerion previously sold its CNS assets, zagociguat and CY3018, to Tisento Therapeutics. As part of this transaction, Cyclerion received an $8 million cash payment and a 10% equity stake in Tisento. The future value and potential monetization of this equity stake represent an indirect driver of revenue growth, contingent on Tisento's success in developing these assets, such as zagociguat which is in a Phase 2b study for MELAS.
4. Upfront and Milestone Payments from New Neuropsychiatric Pipeline Collaborations: Cyclerion is actively pursuing the acquisition of new central nervous system (CNS) assets to rebuild its pipeline, with CYC-126 for treatment-resistant depression (TRD) as its foundational product candidate. As the company progresses its new neuropsychiatric programs, including the anticipated Phase 2 proof-of-concept study for CYC-126 in late 2026, it may seek strategic partnerships. Such collaborations could generate upfront payments and development milestones, providing crucial funding and revenue growth as these assets move through clinical development.

Share Repurchases

Information on significant share repurchases or authorized future share repurchases by Cyclerion Therapeutics (CYCN) over the last 3-5 years is not readily available in the provided search results. Companies with limited capital, especially clinical-stage biopharmaceutical companies, typically prioritize funding research and development over share buybacks.

Share Issuance

• Cyclerion Therapeutics executed a 1-for-20 reverse stock split on May 16, 2023. This action reduced the number of outstanding shares, with the share price adjusting from approximately $0.1912 to $5.38 per share after the split.
• The number of shares outstanding for Cyclerion Therapeutics has fluctuated. As of February 2026, the company had 3.225 million shares outstanding. This compares to 2.43 million shares at the end of 2023, and 3.22 million at the end of 2025.
• From December 2020 to September 2025, the quarterly shares outstanding increased from 0.002 billion (2 million) to 0.003 billion (3 million).

Inbound Investments

• Cyclerion out-licensed praliciguat in 2021.
• The company sold zagociguat and CY3018 to Tisento in 2023.
• In 2024, Cyclerion entered into a non-binding license option agreement for olinciguat.

Outbound Investments

There is no information available in the provided search results indicating that Cyclerion Therapeutics made any significant outbound investments, such as strategic investments in other companies, over the last 3-5 years.

Capital Expenditures

• Cyclerion Therapeutics reported having "Physical Assets US$0" as part of its balance sheet.
• The company's latest twelve-month return on assets was -22.8%, with an average of -56.9% for fiscal years ending December 2020 to 2024.